Searched for: subject%3A%22Oncostatin%255C%2BM%22
(1 - 6 of 6)
document
Rankouhi, T.R. (author), van Keulen, D. (author), Tempel, D. (author), Venhorst, J. (author)
Background: Cardiovascular disease (CVD) is a leading cause of death worldwide. It is predicted that approximately 23.6 million people will die from CVDs annually by 2030. Therefore, there is a great need for an effective therapeutic approach to combat this disease. The European Cardiovascular Target Discovery (CarTarDis) consortium identified...
article 2022
document
Pouwer, M.G. (author)
The thesis discussed several strategies that may contribute to further CVD risk reduction in the future. We described two novel lipid-lowering strategies, we unraveled (part of) the etiology of the cardiovascular safety issues of TKIs that are used for the treatment of CML, and we investigated the dose effects of PFOA on lipoprotein metabolism....
doctoral thesis 2020
document
van Keulen, D. (author), Pouwer, M.G. (author), Emilsson, V. (author), Matic LP, (author), Pieterman, E.J. (author), Hedin, U. (author), Gudnason, V. (author), Jennings, L.L. (author), Holmstrøm, K. (author), Nielsen, B.S. (author), Pasterkamp, G. (author), Lindeman, J.H.N. (author), van Gool, A.J. (author), Sollewijn Gelpke, M.D. (author), Princen, H.M.G. (author), Tempel, D. (author)
OBJECTIVE: Previous studies indicate a role for Oncostatin M (OSM) in atherosclerosis and other chronic inflammatory diseases for which inhibitory antibodies are in development. However, to date no intervention studies with OSM have been performed, and its relation to coronary heart disease (CHD) has not been studied. APPROACH AND RESULTS: Gene...
article 2019
document
van Keulen, D. (author)
Despite the increase in knowledge about cardiovascular diseases and the increase in available drugs since the beginning of the 20th century, one out of three people still dies from cardiovascular diseases. In more than 50% of all cases, atherosclerosis is the underlying pathology and therefore, it is of great importance to develop better...
doctoral thesis 2019
document
van Keulen, D. (author), Pouwer, M.G. (author), Pasterkamp, G. (author), van Gool, A.J. (author), Sollewijn Gelpke, M.D. (author), Princen, H.M.G. (author), Tempel, D. (author)
Aims Endothelial activation is involved in many chronic inflammatory diseases, such as atherosclerosis, and is often initiated by cytokines. Oncostatin M (OSM) is a relatively unknown cytokine that has been suggested to play a role in both endothelial activation and atherosclerosis. We comprehensively investigated the effect of OSM on...
article 2018
document
Verhoeckx, K.C.M. (author), Doornbos, R.P. (author), Witkamp, R.F. (author), van der Greef, J. (author), Rodenburg, R.J.T. (author), TNO Kwaliteit van Leven (author)
Vascular endothelial growth factor (VEGF), oncostatin M (OSM), and granulocyte chemotactic protein-2 (GCP-2/CXCL6) are up-regulated in U937 macrophages and peripheral blood macrophages exposed to LPS, beta-adrenergic receptor (β2-AR) agonists (e.g. zilpaterol, and clenbuterol) and some other agents that induce intracellular cAMP (prostaglandin...
article 2006
Searched for: subject%3A%22Oncostatin%255C%2BM%22
(1 - 6 of 6)